GET DAILY SIGNALSSenti Biosciences (SNTI): Analyst Targets Point to $10 Amid Restructuring Hurdles
Key Takeaways
- The central price target of $10 is the arithmetic mean of three verified, current analyst price targets: H.C. Wainwright at $12, Chardan Capital at $12, and Leerink Partners at $6, giving a range of $6 to $12.
- The stock last traded near $0.16, so reaching $10 would require an upside of roughly 6,000%—a very large move that no analyst treats as routine.
- The strongest support comes from the SENTI-202 oncology program, which produced positive early Phase 1 AML data, and from three Buy ratings with no Hold or Sell recommendations.
- The biggest risks are financial: an ongoing restructuring, dilution from convertible notes, a possible reverse stock split, and Nasdaq listing compliance pressure.
- Readers can track the company's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages for up-to-date context on the ticker.
- Traders seeking automated market coverage can also explore Trending AI Robots for additional analytical tools.
What the Analysts Are Saying
Three current, attributable analyst price targets were reviewed for this analysis. H.C. Wainwright carries a Buy rating with a $12 target, Chardan Capital analyst Geulah Livshits rates the stock Buy and raised the target from $11 to $12 in May 2026, and Leerink Partners initiated coverage with a Buy rating and a $6 target. The arithmetic mean of these three figures is $10.00, rounded to $10, with an approximate range of $6 to $12.
Aggregators display slightly different consensus figures—roughly $9 to $13.50—because they use different inclusion windows and retain older targets. The $10 figure used here is a calculated mean, not an official published consensus. All three analysts rate the stock positively, but the wide gap between the $6 low and the $12 high reflects genuine disagreement about how much the company's balance sheet and restructuring, rather than its science, will shape shareholder value. Chardan's target changes—a cut from $13 to $11 in March 2026 followed by a raise back to $12 in May—illustrate how quickly the outlook shifts for a pre-revenue biotech. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The stock last traded near $0.16, with a market capitalization of roughly $14 million in mid-2026. Reaching $10 would require an increase of approximately 6,000%, a very large move by any standard. A meaningful portion of any apparent path is structural rather than fundamental: the company has authorized a reverse stock split in a range of 1-for-20 to 1-for-50, at the board's discretion, to maintain Nasdaq's $1.00 minimum bid price. A reverse split would mechanically raise the per-share price without changing the company's total market value, so investors should interpret the $10 target in per-share terms with caution.
The fundamental path depends on SENTI-202's clinical progress, the completion of a July 2026 merger agreement that divests the Midco operating business, and the company's ability to secure ongoing funding without excessive dilution. From what I see, this structural element adds an important layer to any valuation discussion.
What Could Support a Move Toward the Target
- SENTI-202 generated positive initial Phase 1 data in AML, which sent the shares sharply higher when announced and underpins the bullish analyst theses.
- All three covering analysts rate the stock Buy, and Chardan's May 2026 target increase signals improving confidence in the clinical, regulatory, and financial position.
- A completed restructuring and note conversion could simplify the corporate structure and clarify the value attributable to the public company.
- The CAR-NK platform, if validated in later trials, represents optionality beyond a single indication.
What Could Prevent the Target From Being Reached
- The company is pre-revenue and heavily reliant on dilutive financing, including convertible notes expected to convert into tens of millions of new shares.
- The pending merger divests the Midco operating subsidiary, creating uncertainty about what assets and cash flow remain at the public company.
- The stock trades well below Nasdaq's $1.00 minimum, and a reverse split—if executed—does not by itself create value.
- Clinical development carries binary risk: later-stage data on SENTI-202 could disappoint or face regulatory delays.
Technical Levels and Market Structure
Reliable, durable technical levels are limited for such a low-priced stock, but two structural reference points matter. The $1.00 Nasdaq minimum bid requirement is the key threshold the company is trying to reclaim, and the roughly $0.342 conversion price on the senior secured convertible notes indicates where substantial new shares could be issued. The stock's status as a sub-$1 issue makes it prone to wide percentage swings on modest dollar moves. I'm watching this closely as compliance deadlines approach.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though the firms do not publish identical timelines. Investors should monitor SENTI-202 clinical data updates, completion of the merger and Midco divestiture, any board decision on the reverse stock split ratio, cash runway and financing announcements, Nasdaq compliance status, and analyst rating or target revisions.
Final Assessment
The central target of $10 is the calculated mean of three analyst price targets spanning $6 to $12, not a guarantee or an official consensus. From a price near $0.16, reaching it would require an enormous move, and part of that apparent gap could be closed mechanically by a reverse stock split rather than by fundamental progress. The SENTI-202 oncology data and unanimous Buy ratings are the clearest supports, while the restructuring, dilution, Nasdaq compliance issues, and clinical uncertainty are the principal obstacles. Investors should focus next on trial data, the reverse split decision, and the company's financing position rather than treating the target as a prediction.
AI Daily Buy/Sell Signals
In my research process, Tickeron's AI Daily Buy/Sell Signals have proven useful for monitoring volatile names like this one. The tool uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a low-priced stock such as SNTI, these signals can help identify potential entry points and track trend changes more efficiently than manual methods alone. I find it complements traditional analysis when reviewing pre-revenue biotechs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SNTI in -12.12% downward trend, declining for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SNTI declined for three days, in 273 of 312 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNTI as a result. In 79 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Aroon Indicator for SNTI entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SNTI's RSI Oscillator exited the oversold zone, 36 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for SNTI just turned positive on November 11, 2026. Looking at past instances where SNTI's MACD turned positive, the stock continued to rise in 38 of 47 cases over the following month. The odds of a continued upward trend are 81%.
Following a +16.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNTI advanced for three days, in 194 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SNTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.465) is normal, around the industry mean (3.498). P/E Ratio (-0.095) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (166.667) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. SNTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement